rs2018643 — SLC2A9 SLC2A9 rs2018643

SLC2A9 rs2018643 — A Tag Variant at the Dominant Urate-Control Locus

Serum uric acid (urate) is one of the most heritable metabolic traits in humans, and a single genomic region on chromosome 4 — spanning the SLC2A9 gene — accounts for more of that heritability than any other locus in the genome. The rs2018643 variant sits within an intron of SLC2A9 and tags a haplotype associated with the regulation of renal urate clearance. While no peer-reviewed publication has tested rs2018643 as the primary variant of interest, its position within the SLC2A9 locus and its allele frequency pattern are consistent with participation in the broad multi-signal genetic architecture of this region.

SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9: a voltage-gated urate transporter in the kidney proximal tubule that drives urate reabsorption from tubular fluid back into the bloodstream; it transports urate 45–60× more efficiently than glucose despite its name. Two isoforms exist: GLUT9a (long isoform) at the basolateral membrane and GLUT9b (short isoform) at the apical membrane of proximal tubule cells. Together they mediate the majority of renal urate reabsorption, making SLC2A9 the master rheostat for blood urate levels.

The Mechanism

rs2018643 is located at GRCh38 chr4:9,945,497, approximately 3 kb from the known GWAS lead variant rs12498742 and within the same intronic region of SLC2A9 that has been implicated in regulatory control of transporter expression. Intronic variants in SLC2A9 — including the well-characterised rs11942223 (which lies approximately 16 kb telomeric) — act by modulating SLC2A9 gene expression or splicing rather than altering the GLUT9 protein sequence.

Epistatic mapping of the SLC2A9 locus²² Epistatic mapping of the SLC2A9 locus
Wei et al. Abundant local interactions in the 4p16.1 region suggest functional mechanisms underlying SLC2A9 associations with human serum uric acid. Hum Mol Genet, 2014 identified five genome-wide significant SNP-SNP interaction pairs clustered in an intergenic enhancer region upstream of SLC2A9, with interacting variants enriched at chromatin marks active in liver (HepG2) and precursor red blood (K562) cells. The proposed mechanism is that regulatory variants — potentially including rs2018643 and nearby tag SNPs — modulate SLC2A9 transcription through enhancer elements, with the net effect being altered GLUT9 protein abundance and urate reabsorption efficiency.

The T allele at rs2018643 (the GRCh38 plus-strand reference) follows the frequency pattern typical of SLC2A9 risk alleles: it is at highest frequency in East Asians (~90%), intermediate in Europeans (~57%), and at its lowest in African-ancestry populations (~34%), where gout historically has been less prevalent under traditional dietary conditions. The C allele shows the complementary pattern — most common in African populations (~66%), consistent with it being the allele associated with more efficient urate clearance.

The Evidence

Discovery and strength of the SLC2A9 urate signal: Two landmark 2008 Nature Genetics papers identified SLC2A9 as the dominant genetic locus for serum urate. Döring et al.³³ Döring et al.
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet, 2008 found intronic SLC2A9 variants explaining 1.2% of urate variance in men but up to 6% in women — the sex-specific effect mediated by estrogen's independent stimulation of renal urate excretion. Vitart et al.⁴⁴ Vitart et al.
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet, 2008 independently confirmed SLC2A9 as the single strongest determinant of serum urate, with variants explaining 1.7–5.3% of urate variance and also associating with low fractional urate excretion and gout.

Large-scale meta-analysis confirmation: Kolz et al.⁵⁵ Kolz et al.
Kolz M et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet, 2009 meta-analysed 14 studies and found SLC2A9 to be the dominant signal at P = 5.2×10⁻²⁰¹ — one of the most significant genetic associations ever reported for a quantitative metabolic trait. The rs734553 minor allele (another intronic SLC2A9 variant) showed pronounced sex-specific urate-lowering in women.

Multi-signal complexity: The SLC2A9 locus is genetically complex. Wei et al.⁶⁶ Wei et al.
Wei W-H et al. Abundant local interactions in the 4p16.1 region suggest functional mechanisms underlying SLC2A9 associations with human serum uric acid. Hum Mol Genet, 2014 found at least five independent marginal effects plus three significant epistatic pairs within a single 4p16.1 region, collectively explaining 1.5% additional variance beyond the single lead variant. rs2018643, located between the lead GWAS SNPs, likely captures some portion of this complex signal.

Gene-diet interaction: Two studies from the Merriman group demonstrated that the protective (C) allele at SLC2A9 intronic variants is sensitive to dietary fructose: in a fructose-challenge study, Dalbeth et al.⁷⁷ Dalbeth et al.
Dalbeth N et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load. Ann Rheum Dis, 2013 found that the C allele attenuated the urate spike after 64 g fructose in Caucasians but not in Māori or Pacific Islander participants. A follow-up study of sugar-sweetened beverages⁸⁸ study of sugar-sweetened beverages
Dalbeth N et al. Ann Rheum Dis, 2014 found that regular SSB intake reversed the gout protection, increasing gout risk by 15% per daily serving even in C allele carriers. This gene-environment interaction is the most clinically actionable finding at the SLC2A9 locus.

Practical Actions

The most important message from the SLC2A9 locus is dietary: regardless of which specific allele you carry, fructose from sugar-sweetened beverages raises serum urate through two converging mechanisms — direct hepatic urate production and competition for renal tubular urate transporters. T allele (risk) carriers have a genetically elevated urate baseline; C allele carriers have a lower baseline that is vulnerable to being erased by fructose.

Women with T alleles warrant particular attention around menopause. The SLC2A9 intronic signal has a disproportionately large effect in women (up to 6% of urate variance explained vs. 1.2% in men) because estrogen independently promotes renal urate excretion. When estrogen declines at menopause, this hormonal buffer disappears, and genetic urate elevation that was previously compensated can emerge as clinical hyperuricemia.

Interactions

Within the SLC2A9 locus — independent signals: rs2018643 tags part of the broad SLC2A9 association signal, but two other variants capture independent effects: rs11942223 (an intronic signal approximately 16 kb away, independent of rs3733591, r² only 0.03–0.05 between them) and rs3733591 (the Arg265His missense variant). Carrying risk alleles at rs2018643 and rs3733591 and rs11942223 can stack additively, as these signals do not substantially overlap.

ABCG2 rs2231142 (Q141K): ABCG2 is the intestinal urate efflux transporter. The Q141K risk allele (A allele of rs2231142) reduces ABCG2 activity and raises serum urate through a completely different pathway from SLC2A9's renal mechanism. Carrying SLC2A9 T alleles and ABCG2 rs2231142 A alleles simultaneously can produce serum urate above 7 mg/dL even in the absence of extreme dietary purine loading.

Fructose and sugar-sweetened beverages: The gene-diet interaction documented for SLC2A9 protective alleles applies to the broader locus signal. T allele carriers lack the natural advantage of increased urate excretion, making fructose restriction and SSB elimination the highest-leverage dietary intervention available.